Cytoki Pharma is at the forefront of developing innovative therapies that leverage the innate properties of interleukin-22 (IL-22) to combat metabolic diseases such as obesity and type 2 diabetes, as well as conditions involving epithelial injury like inflammatory bowel disease (IBD). Their lead product, CK-0045, is a long-acting IL-22 analogue currently undergoing Phase 2 clinical trials. This novel therapeutic approach aims to provide significant disease modification by promoting healthy weight loss and improving various metabolic parameters, including insulin sensitivity and liver health. The company’s focus on harnessing IL-22's natural biology positions it uniquely in the biotechnology landscape, addressing unmet medical needs in cardiometabolic health.

Cytoki's technology centers around lipidated IL-22 analogues, which are engineered to enhance the therapeutic potential of IL-22 by extending its circulation time in the body and allowing for subcutaneous delivery. This lipidation process involves the attachment of a small fatty acid chain to the IL-22 protein, which protects it from rapid clearance and degradation, thereby maintaining its efficacy. The lipidated form of IL-22 binds non-covalently to serum albumin in the bloodstream, creating a dynamic equilibrium that facilitates targeted receptor engagement. This innovative mechanism not only enhances the therapeutic profile of IL-22 but also positions Cytoki's treatments as first-in-class options for managing metabolic diseases and promoting epithelial healing.

Denmark

Cytoki Pharma is a privately held Danish clinical stage biotechnology company pioneering a new class of medicines that harness IL-22 biology to drive improved outcomes for metabolic disease and IBD.

Cytoki Pharma

Company Details